ATR-107

Synonyms: PF-05230900
ATR-107 (PF-05230900) 是一种靶向白细胞介素-21 受体 (IL-21R) 的人源化单克隆抗体抑制剂,其在食蟹猴中的 Kₐ 值为 2-4 nM、在小鼠中为 16 nM、在大鼠中为 71 nM,可用于系统性红斑狼疮和气囊炎症相关的研究。
ATR-107
产品编号: MS-R34640 纯度: 99.9% 分子量: 143.42 kDa
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

ATR-107 (PF-05230900) 是一种靶向白细胞介素-21 受体 (IL-21R) 的人源化单克隆抗体抑制剂,其在食蟹猴中的 Kₐ 值为 2-4 nM、在小鼠中为 16 nM、在大鼠中为 71 nM,可用于系统性红斑狼疮和气囊炎症相关的研究。

生物实验数据

生物活性 ATR-107 (PF-05230900) is a humanized monoclonal antibody inhibitor targeting the interleukin-21 receptor (IL-21R), with a Kₐ value of 2-4 nM in cynomolgus monkeys, 16 nM in mice, and 71 nM in rats, and it can be used for research related to systemic lupus erythematosus and air pouch inflammation.
IC50 & Target

IL21R/CD360

体外研究
(In Vitro)

ATR-107 (100 μg/mL; 24 h) 在人单核细胞来源树突状细胞中诱导的 DC50 内化指数显著高于贝伐珠单抗,且显著低于波科利珠单抗,这与其较高的临床抗药物抗体发生率一致。
ATR-107 (50 μg/mL; 7-day total incubation, with BrdU added for the final 24 h) 可在人外周血单个核细胞 (PBMCs) 中诱导显著的 CD4+ T 细胞增殖,在约 30%的健康供者中呈阳性应答,这与其较高的临床抗药物抗体发生率一致。
ATR-107 (100 μg/mL; 16 h (MAPPs assay)) 具有 11 个计算机模拟预测的免疫原性 T 细胞表位,其中 9 个与通过 MAPPs 检测到的 MHC-II 相关肽段重叠,表明其具有较高的 T 细胞介导免疫原性潜力。

体内研究
(In Vivo)

ATR-107 (10-250 mg/kg; i.v., s.c.; 每周;13 周) 仅在以每周 10 mg/kg 静脉注射 (i.v.) 且给药≥3 次后,会在 Sprague-Dawley 大鼠中引发免疫介导的肝损伤 (坏死、桥接纤维化、肝酶升高);单纯抗药物抗体 (ADA) 的存在不足以诱发肝损伤,因为以 10 mg/kg 皮下注射 (s.c.) 时 ADA 发生率达 100%(未出现肝损伤),表明该效应具有给药途径依赖性。
ATR-107 (1-10 mg/kg; i.v.; weekly; up to 4 doses) 在雌性 Sprague-Dawley 大鼠中诱导肝损伤,该损伤需要≥3 次每周静脉注射剂量,与高 ADA 滴度相关,并会导致肝酶短暂升高,同时出现的微观形态学改变与 13 周研究结果一致。
ATR-107 (0.1-10 mg/kg; i.v.; weekly; 3 or 4 doses) 不会对雌性裸鼠造成肝损伤,这表明免疫功能健全的 Sprague-Dawley 大鼠中观察到的肝脏效应需要有功能的免疫系统 (及由此产生的 ADA 形成)。
ATR-107 (0.1-250 mg/kg; i.v., s.c.; weekly; up to 4 doses) 会在 CD-1 小鼠中引发剂量依赖性过敏性死亡,该效应在静脉注射 (i.v.)≥2 次后出现 (呈以 1 mg/kg i.v.为中心的钟形曲线),且与高 ADA 发生率相关;而皮下注射 (s.c.) 给药未观察到此类效应。
ATR-107 (10-100 mg/kg; i.v., s.c.; weekly; 13 weeks) 在食蟹猴 (Cynomolgus monkeys) 的任一剂量或给药途径下,均未出现与 ATR-107 相关的死亡、临床观察异常、临床病理变化、脏器重量改变或宏观/微观组织学异常;且低剂量下抗药物抗体 (ADA) 发生率较低,高剂量下 ADA 发生率为 0%。

Animal Model: Sprague-Dawley (Crl:CD[SD]) (male and female, 7 to 9 weeks old, ≥170 g)
Dosage: 10 mg/kg; 50 mg/kg; 250 mg/kg (i.v.); 10 mg/kg; 250 mg/kg (s.c.)
Administration: i.v.; weekly; 13 weeks; s.c.; weekly; 13 weeks
Result: Caused 1 female death on day 16 due to marked midzonal to diffuse bridging liver necrosis at 10 mg/kg i.v. At end of dosing phase, induced moderate to marked diffuse bridging liver fibrosis with parenchymal nodules, single-cell hepatocyte necrosis, vacuolation, pigment-laden macrophages, bile duct hyperplasia/degeneration/necrosis, and eosinophil-rich mixed inflammation in 2 males and 2 females, and elevated ALT (70-109 IU/L), AST (194-383 IU/L), and AP (239-281 IU/L) in 3 males at 10 mg/kg i.v. At end of recovery phase, resulted in minimal to moderate diffuse bridging fibrosis in 1 male and 4 females, and elevated ALT (115 IU/L), AST (251 IU/L), and AP (186 IU/L) in 1 male at 10 mg/kg i.v. Induced 100% ADA incidence (log titers >4.74) at end of dosing and recovery phases at 10 mg/kg i.v. Showed no ATR-107-related liver findings, mortality, or clinical pathology changes at 50 mg/kg, 250 mg/kg i.v., and 10 mg/kg, 250 mg/kg s.c. Resulted in 33.3% ADA incidence at 50 mg/kg i.v., 0% at 250 mg/kg i.v., 100% at 10 mg/kg s.c., and 66.7% at 250 mg/kg s.c. at end of dosing phase. Increased serum ATR-107 exposures with dose at i.v. routes. Had lower serum ATR-107 exposure at 250 mg/kg s.c. than at 50 mg/kg i.v.
Animal Model: Sprague-Dawley (Crl:CD[SD]) (female, 7 to 9 weeks old, ≥170 g)
Dosage: 1 mg/kg; 10 mg/kg
Administration: i.v.; weekly; up to 4 doses
Result: Caused no mortality, but elevated ALT (189-1329 IU/L) and AST (294-2079 IU/L) first detected on day 15 (after 3rd dose) in 9/20 and 3/20 rats respectively, values returned to control levels by day 20 then re-elevated in 2/10 rats on day 22 (after 4th dose) at 1 mg/kg i.v. Induced liver microscopic findings (hepatocellular degeneration/necrosis, eosinophilic cytoplasmic droplets, mixed cell inflammation with slight bile duct hyperplasia) after 3 or 4 doses, with necrotic areas and cytoplasmic droplets immunopositive for rat IgG, IgM, and C3 at 1 mg/kg i.v. Detected ADAs at low titers prior to 3rd dose, with high titers (2.75 to >4.74 log titer) in all rats after 3 or 4 doses, and sharp drop in serum ATR-107 concentrations after 3rd dose at 1 mg/kg i.v. Led to 1 female elective euthanasia on day 22 after 4 doses, with marked midzonal hepatocellular necrosis and eosinophilic cytoplasmic droplets at 10 mg/kg i.v. Detected elevated ALT (170-220 IU/L) in 2/20 rats on day 15 (after 3rd dose) and 1/10 rats on day 22 (after 4th dose) at 10 mg/kg i.v. Observed liver microscopic findings (hepatocellular degeneration/necrosis, eosinophilic cytoplasmic droplets) after 4 doses in 1/10 rats, with immunopositivity for rat IgG, IgM, and C3 in affected areas at 10 mg/kg i.v. Detected ADAs in 7/10 rats after 3 doses and 9/10 rats after 4 doses, with measurable but lower serum ATR-107 concentrations after 3rd/4th doses compared to earlier doses at 10 mg/kg i.v.
Animal Model: Crl:CD-1 (ICR) (male and female, 7 to 9 weeks old, ~22 g)
Dosage: 0.1 mg/kg; 1 mg/kg; 10 mg/kg; 250 mg/kg (i.v.); 10 mg/kg; 250 mg/kg (s.c.)
Administration: i.v.; weekly; up to 4 doses (dosing discontinued after 2 or 3 doses in 1 mg/kg i.v. group); s.c.; weekly; up to 4 doses
Result: Caused dose-dependent anaphylactic mortality after ≥2 weekly i.v. doses, with a bell-shaped incidence curve centered at 1 mg/kg i.v. (20/76 animals at 1 mg/kg, 5/76 at 0.1 mg/kg, 4/76 at 10 mg/kg, 1/76 at 250 mg/kg). Induced clinical signs (decreased motor activity, convulsions, ataxia, dyspnea, hunched posture, cool to touch, ptosis, tachypnea, bradypnea) within 4 minutes to 1 hour of dosing at all i.v. doses. Observed mild to moderate pulmonary thrombi with increased intravascular neutrophils in some 1 mg/kg i.v. animals that died. Showed no ATR-107-related body weight, food consumption, or macroscopic/microscopic findings in surviving animals (except clinical signs in 0.1 and 1 mg/kg i.v. groups) at i.v. doses. Resulted in 77% (54/70) ADA incidence at 0.1 mg/kg i.v., 73% (41/56) at 1 mg/kg i.v., 7% (5/71) at 10 mg/kg i.v., and 0% (0/74) at 250 mg/kg i.v. Showed no mortality, clinical signs, or ATR-107-related findings at 10 mg/kg and 250 mg/kg s.c. Resulted in 22% (16/74) ADA incidence at 10 mg/kg s.c. and 0% (0/70) at 250 mg/kg s.c.
Animal Model: Cynomolgus Monkey (male and female, ~3 to 5 years old, ~2 to 6 kg)
Dosage: 10 mg/kg; 30 mg/kg; 100 mg/kg (i.v.); 10 mg/kg; 100 mg/kg (s.c.)
Administration: i.v.; weekly; 13 weeks; s.c.; weekly; 13 weeks
Result: Caused no ATR-107-related mortality, clinical observations, clinical pathology changes, organ weight changes, or macroscopic/microscopic tissue findings at any dose or route. Resulted in 8.3% ADA incidence at 10 mg/kg i.v., 16.7% at 10 mg/kg s.c., and 0% at all higher i.v. and s.c. doses.
Clinical Trial
NCT NumberSponsorConditionStart DatePhase
NCT01162889Pfizer
Healthy
2010-06PHASE1
性状 液体
颜色 Colorless to light yellow

化学信息

分子量 143.42 kDa
别名 PF-05230900

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Shipping with dry ice.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础